VC: Esprit adds $91M, ESBATech gains $41M

Esprit Pharma has rounded up almost $91 million in its second round of venture capital. Firms participating in the Series B round included existing investors New Enterprise Associates, Apax Partners, Domain Associates and Montagu Newhall Global Partners plus new investors Oak Investment Partners and clients advised by Performance Equity Management. "While it's been just over a year since we began operations, Esprit has experienced strong growth," said John T. Spitznagel, Esprit's chairman and CEO. "In this relatively short period of time, we have applied our Buy and Build, Search and Develop strategy to acquiring four approved products, building a commercial organization including more than 200 sales and marketing professionals, and recently acquiring our first pipeline product."

- take a look at the release on the round

ALSO: Switzerland's ESBATech has raised $41 million from a consortium of U.S. and European investors in its second round of venture capital. SV Life Sciences, Clarus Ventures, HBM BioVentures and HBM BioCapital all participated with existing investors such as Novartis Venture Fund, BioMedinvest and VI Partners. The company has been building a human antibody fragment platform. Release

PLUS: Biodel, which develops drug delivery technologies, has raised $21 million in its second round. Release